(Rhone Poulenc Pharma Inc) said itplans to spend 29 mln dlrs over the next five years forresearch and development in Canada. It said the investmentdepends upon passage of a federal government bill whichproposes greater protection for holders of drug patents.    The company said it will spend 7.9 mln dlrs to upgrade itsMontreal operations.    It said the new patent law would give drug companies reasonable protection from generic drug copying of newcompounds. Reuter&#3;